9:00am - 5:00pm

Office Hours Mon. - Fri.


Call Us For Free Consultation




Safety Study of MGD009 in B7-H3-expressing Tumors

Estimated reading time: < 1 min


Mesothelioma|Bladder Cancer|Melanoma|Squamous Cell Carcinoma of the Head and Neck|Non Small Cell Lung Cancer|Clear Cell Renal Cell Carcinoma|Ovarian Cancer|Thyroid Cancer|Breast Cancer|Pancreatic Cancer|Prostate Cancer|Colon Cancer|Soft Tissue Sarcoma

Estimated Enrollment: 114

Age Group: 18 Years and older   (Adult, Senior)

Gender: All

Study Type: Interventional

Study Design Allocation: Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment

Study ID Numbers: CP-MGD009-01

Study First Received: November 20, 2015

Last Updated: August 10, 2016

Estimated Primary Completion Date: December 2018

Primary Outcome Measures:

Number of participants with adverse events|Peak plasma concentration|Number of participants that develop anti-drug antibodies|Change in tumor volume

Sponsors and Collaborators:


Result Received: No Study Results Posted

Website Link: https://ClinicalTrials.gov/show/NCT02628535

Was this article helpful?
Views: 16